← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mclean Hospital
Belmont, MA
$622,624,032
Total funding
470
Grants
Funding over time
peak $57.4M · FY2006–25$100M$75M$50M$25M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$618,625,876 · 465
NSF$5,181,230 · 6
By mechanism
R01$317,564,219 · 160
P50$58,687,709 · 42
N01$42,305,485 · 7
R21$29,710,505 · 71
U10$22,643,501 · 1
K23$19,248,015 · 26
Investigators at Mclean Hospital
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
The National Drug Abuse Treatment Clinical Trials Network$4,700,000
UG1 · FY2019 · DA
Antibody-based therapy for fentanyl-related opioid use disorder$4,202,550
UG3 · FY2023 · DA
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making$3,225,604
P50 · FY2020 · MH
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making$3,174,635
P50 · FY2021 · MH
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making$3,167,713
P50 · FY2022 · MH
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making$3,162,041
P50 · FY2023 · MH
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making$3,151,881
P50 · FY2024 · MH
NIH NATIONAL BRAIN AND TISSUE REPOSITORYPERIOD OF PERFORMANCE: 09/01/2019 - 08/31/2021 (UNCHANGED)TOTAL CONTRACT AMOUNT: $4,937,543.50 (UNCHANGED)TOTAL OBLIGATED AMOUNT: $4,937,543.50 (UNCHANGED)$2,926,005
N01 · FY2023 · DA
Dimensions of Success: Transforming Quality Assessment in Middle School Science and Engineering$2,790,474
· FY2021 · EDU
NIH NEUROBIOBANK BRAIN AND TISSUE REPOSITORYCONTRACT TYPE: COST, OPTIONPERIOD OF PERFORMANCE: 09/01/2019 TO 08/31/2020$2,755,590
N01 · FY2021 · DA
Silvio O. Conte Center for Stress Peptide Advanced Research, Education, & Dissemination (SPARED) at McLean Hospital$2,716,065
P50 · FY2021 · MH
Silvio O. Conte Center for Stress Peptide Advanced Research, Education, & Dissemination (SPARED) at McLean Hospital$2,703,016
P50 · FY2019 · MH
Silvio O. Conte Center for Stress Peptide Advanced Research, Education, & Dissemination (SPARED) at McLean Hospital$2,696,386
P50 · FY2022 · MH
Silvio O. Conte Center for Stress Peptide Advanced Research, Education, & Dissemination (SPARED) at McLean Hospital$2,690,971
P50 · FY2020 · MH
Silvio O. Conte Center for Stress Peptide Advanced Research, Education, & Dissemination (SPARED) at McLean Hospital$2,647,321
P50 · FY2023 · MH
NIH NATIONAL BRAIN AND TISSUE REPOSITORY$2,615,663
N01 · FY2024 · DA
Combining Computational Methods, RDoC, and Big Neuroimaging Data to Understand Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Disease$2,432,945
RF1 · FY2022 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,415,140
R01 · FY2018 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,344,010
R01 · FY2020 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,341,700
R01 · FY2019 · AG